膵臓癌治療法の世界市場2019-2023

◆英語タイトル:Global Pancreatic Cancer Therapeutics Market 2019-2023
◆商品コード:IRTNTR30555
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月27日
◆ページ数:115
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、膵臓癌治療法の世界市場について調査・分析し、市場概要、市場環境、膵臓癌治療法市場規模、製品別(ターゲット療法、化学療法)分析、種類別(膵外分泌癌、膵内分泌癌)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・膵臓癌治療法の世界市場概要
・膵臓癌治療法の世界市場環境
・膵臓癌治療法の世界市場動向
・膵臓癌治療法の世界市場規模
・膵臓癌治療法の世界市場:業界構造分析
・膵臓癌治療法の世界市場:製品別(ターゲット療法、化学療法)
・膵臓癌治療法の世界市場:種類別(膵外分泌癌、膵内分泌癌)
・膵臓癌治療法の世界市場:地域別市場規模・分析
・膵臓癌治療法の北米市場規模・予測
・膵臓癌治療法のヨーロッパ・中東・アフリカ市場規模・予測
・膵臓癌治療法のアジア太平洋市場規模・予測
・膵臓癌治療法の主要国分析
・膵臓癌治療法の世界市場:意思決定フレームワーク
・膵臓癌治療法の世界市場:成長要因、課題
・膵臓癌治療法の世界市場:競争環境
・膵臓癌治療法の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Availability of improved diagnostic modalities to drive growth in the market. To combat the shortcomings in the prognosis of pancreatic cancer, advanced diagnostic aids based on the principles of complementary DNA (cDNA) fingerprinting, PCR, and DNA microarray, and molecular profiling are being developed. Technavio’s analysts have predicted that the pancreatic cancer therapeutics market will register a CAGR of more than 8% by 2023.
Market Overview
Robust pipeline and new drug approvals
The pipeline for the treatment of pancreatic cancer includes novel therapeutic approaches, including vaccines, gene therapy, stem cell therapy, and targeted therapy products.
High cost of treatments
Pancreatic cancer requires long term treatment, which increases the treatment cost and the economic burden on patients.
For the detailed list of factors that will drive and challenge the growth of the pancreatic cancer therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the robust pipeline and new drug approvals and the availability of improved diagnostic modalities, will provide considerable growth opportunities to pancreatic cancer therapeutics manufactures. Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Targeted therapy – Market size and forecast 2018-2023
• Chemotherapy – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
• Exocrine pancreatic cancer
• Endocrine pancreatic cancer
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eli Lilly
• F. Hoffmann-La Roche
• Novartis
• Pfizer
• Shire
PART 15: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Therapies in late stage development for pancreatic cancer
Exhibit 07: Market definition – Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Product – Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Targeted therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Targeted therapy – Year-over-year growth 2019-2023 (%)
Exhibit 23: Chemotherapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Chemotherapy – Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Key leading countries
Exhibit 36: Market opportunity
Exhibit 37: Decision framework
Exhibit 38: New drug approvals for pancreatic cancer
Exhibit 39: Patent expiration dates for therapies for pancreatic cancer
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Immunotherapy products under research
Exhibit 42: Combination therapies for pancreatic cancer
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Eli Lilly – Vendor overview
Exhibit 49: Eli Lilly – Business segments
Exhibit 50: Eli Lilly – Organizational developments
Exhibit 51: Eli Lilly – Geographic focus
Exhibit 52: Eli Lilly – Segment focus
Exhibit 53: Eli Lilly – Key offerings
Exhibit 54: F. Hoffmann-La Roche – Vendor overview
Exhibit 55: F. Hoffmann-La Roche – Business segments
Exhibit 56: F. Hoffmann-La Roche – Organizational developments
Exhibit 57: F. Hoffmann-La Roche – Geographic focus
Exhibit 58: F. Hoffmann-La Roche – Segment focus
Exhibit 59: F. Hoffmann-La Roche – Key offerings
Exhibit 60: Novartis – Vendor overview
Exhibit 61: Novartis – Business segments
Exhibit 62: Novartis – Organizational developments
Exhibit 63: Novartis – Geographic focus
Exhibit 64: Novartis – Segment focus
Exhibit 65: Novartis – Key offerings
Exhibit 66: Pfizer – Vendor overview
Exhibit 67: Pfizer – Business segments
Exhibit 68: Pfizer – Organizational developments
Exhibit 69: Pfizer – Geographic focus
Exhibit 70: Pfizer – Segment focus
Exhibit 71: Pfizer – Key offerings
Exhibit 72: Shire – Vendor overview
Exhibit 73: Shire – Business segments
Exhibit 74: Shire – Organizational developments
Exhibit 75: Shire – Geographic focus
Exhibit 76: Shire – Key offerings
Exhibit 77: Validation techniques employed for market sizing
Exhibit 78: List of abbreviations



【掲載企業】

Eli Lilly
F. Hoffmann-La Roche
Novartis
Pfizer
Shire

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[膵臓癌治療法の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆